Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.

ABSTRACT:

Background

We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers.

Methods

The study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST). Patients were categorized as 20 "controlled disease" (stable disease, partial response, or complete response) or 37 progressive disease). We used 3D-slicer to segment target lesions on standard-of-care, pretreatment contrast enhanced CT scans. We extracted 610 features (10 histogram-based features and 600 second-order texture features) from each volume of interest. Least absolute shrinkage a

SUBMITTER: Colen RR 

PROVIDER: S-EPMC8051405 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature